CIRCIO HOLDING ASA
CRNA
ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE
Circio Holding ASA Notice of extraordinary general meeting on 25 August 2026
Oslo, Norway, 4 August 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, hereby calls for an extraordinary general meeting (the "EGM") to be held on 25 August 2026 to resolve inter alia the election of new members of the Board of Directors.
The EGM will be held on Tuesday 25 August 2026 at 11:00 hours (CEST) as a physical meeting at the Company's offices at Tordenskiolds gate 2, 0160 Oslo, Norway.
The notice and agenda of the EGM are attached hereto, including further information on advance voting, power of attorney and physical participation. The notice and the nomination committee's recommendation are made available on the Company's webpage www.circio.com (https://www.circio.com/) under the heading "Investors".
The biographies of the proposed new members of the Board of Directors will be presented in a separate stock exchange notice.
This information is subject to disclosure under the Norwegian Securities Act section 5-12 and the requirements of Oslo Børs' Continuing Obligations.
For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com
Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
About Circio Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.